Cybin Corp. is a life sciences company that is focused on the pharmaceutical development of psychedelic products as well as the functional mushroom market. The emerging business is laser focused on the development of products and protocols in the psychedelic, pharmaceutical and nutraceutical sectors and has an intellectual property (IP) strategy that revolves around psychedelic delivery mechanisms, synthetic compounds, extraction methods, isolation of chemical compounds, new drug formulations, and protocol regimens.
Cybin is focused on furthering research and development of psilocybin-based medications through Serenity Life Sciences Inc., as well as the nutraceutical mushroom market through Natures Journey Inc.. These wholly owned divisions make Cybin a multi-faceted growth opportunity and we are bullish on the structure of the operation due to the amount of potential synergies that can be found between the divisions.
Positioned for Growth via Natures Journey and Serenity Life Sciences
According to the World Health Organization, more than 700 million people across the globe are afflicted with some sort of mental illness, addiction, or eating disorder. Cybin is focused on researching and developing treatments for these indications and we are favorable on the size of the markets that it is levered to.
Through Natures Journey, Cybin is executing on a strategy that is focused on developing proprietary functional mushroom products that potentially promote mental serenity and acuity, immune boosting, detoxification and overall general health and wellness. The company’s functional mushroom product line will target cognitive flexibility, immune boosting, energy, and detoxification. Cybin’s launch strategy will be primarily geared towards ecommerce sales and we are favorable on the track record that is associated with the digital team that is in place.
Through Serenity Life Sciences, Cybin plans to bring new psychedelic therapies to market and aims to secure strategic transfer agreements after a Phase 1 and a Phase 2 clinical trial, if the trials yield favorable results and Cybin receives all necessary regulatory approvals. The company has a fast track strategy as well as a path to fully approved psychedelic-based pharmaceutical products and this could to prove to be a major growth driver for the business.
Focused on Several Emerging Markets
Cybin is focused on psychedelic research opportunities in three countries: Canada, the USA and Jamaica, with plans to globally expand. Cybin has provided an update on the state of the business in these jurisdictions below and are favorable on the geographic diversity of the business:
- Jamaica: Cybin has signed collaboration agreements with the University of the West Indies, Caribbean Institute for Health Research and the Scientific Research Council.
- Canada: Cybin is working with high-level pharmaceutical, institutional and government relations individuals to advance the acceptance of psychedelics for medical use. Earlier this year, the company announced a partnership with the Toronto Centre for Psychedelic Science to expand its psilocybin IP portfolio and to facilitate clinical trials and treatment protocols.
Led by an Experienced Management Team
One of the main reasons we are excited about Cybin is due to the strength of the management team. The company is led by a management team and advisory team that are comprised of industry veterans who have vast experience in the psychedelic, pharmaceutical, and nutraceutical sectors. The management team has previously successfully completed multiple clinical trials and has brought new drugs to market and we are favorable on such experience.
One of the most invaluable members of the team is Chief Medical Officer Jukka Karjalainen Ph.D., M.D. He has 25 years of experience in the pharmaceutical industry that spans multiple medical specialties, academic, clinical research regulatory affairs, preclinical, and clinical drug development from Phase I to Phase IV.
Dr. Karjalainen has managed multiple corporate Phase 2-3 clinical registration trials and 30 local Phase 3b and 4 trials in over 150 clinical investigator sites. He is the former Director of medical and regulatory affairs and corporate Vice President at Biovail Pharmaceuticals as well as the former Medical Director at Eli Lilly and Company (Finland).
With this type of leadership, Cybin is well positioned to execute on previously announced initiatives and we are bullish on the amount of human capital that is associated with the operation. We are favorable on the direction that the management is taking the business and believe that it has a clear line of sight for near-term revenues through the sale of nutraceutical products.
A Growth Story to be Aware of
The life sciences company is in the early innings of a major growth cycle and has significant potential catalysts for growth. We believe that Cybin is an opportunity to be aware of and one that we will continue to closely follow.
If you are interested in learning more about the life sciences company, please send an email to email@example.com to learn more and to be added to our distribution list.
 Source: World Health Organization
 Certain statements regarding functional mushrooms have not been evaluated by the United States Food and Drug Administration (the “FDA) or other similar regulatory authorities. There is no assurance that functional mushrooms can be used to diagnose, treat, cure or prevent any disease or condition and robust scientific research and clinical trials are needed.
 Certain statements regarding psilocybin have not been evaluated by the FDA or other similar regulatory authorities, nor has the efficacy of psilocybin been confirmed by FDA-approved research. There is no assurance that psilocybin can be used to diagnose, treat, cure or prevent any disease or condition and robust scientific research and clinical trials are needed
Pursuant to an agreement between StoneBridge Partners LLC and Cybin Corp. we have been hired for a period of 180 days beginning July 1, 2020 and ending January 1, 2021 to publicly disseminate information about (Cybin Corp.) including on the Website and other media including Facebook and Twitter. We are being paid $7,500 per month (Cybin Corp.) for or were paid “0” shares of restricted common shares. We own zero shares of (Cybin Corp.), which we purchased in the open market. We plan to sell the “ZERO” shares of (Cybin Corp.) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (Cybin Corp.) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.